Kinetoplast as a potential chemotherapeutic target of trypanosomatids

Current Pharmaceutical Design

Volumn 14, Issue 9, 2008, Pages 847-854

  Motta, Maria Cristina Machado ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Chemotherapy; DNA binding drugs; Kinetoplast; Topoisomerases; Trypanosomatids

Indexed keywords

9 AMINOCAMPTOTHECIN; ACRIFLAVINE; AMAROGENTIN; AMSACRINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LAPACHONE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CATENATED DNA; CLOROBIOCIN; COUMAMYCIN; COUMARIN DERIVATIVE; DIMINAZENE ACETURATE; DIOSPYRIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; INTOPLICINE; IRINOTECAN; KINETOPLAST DNA; MITOCHONDRIAL DNA; NALIDIXIC ACID; NOVOBIOCIN; OFLOXACIN; OXOLINIC ACID; SAINTOPIN; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG;

DNA BINDING; DNA REPLICATION; DNA SYNTHESIS; DRUG TARGETING; KINETOPLAST; LEISHMANIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRYPANOSOMA;

ANIMALS; ANTIPROTOZOAL AGENTS; DNA, KINETOPLAST; DRUG DELIVERY SYSTEMS; HUMANS; LEISHMANIA; LEISHMANIASIS; TRYPANOSOMA; TRYPANOSOMIASIS;

EID: 44349118534     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784041051     Document Type: Review

References (94)

1. De Souza W. Cell biology of Trypanosoma cruzi. Int Rev Cytol 1984; 86: 197-283.
2. Shlomai J. The assembly of kinetoplast DNA. Parasitol Today 1994; 10: 341-6.
3. Esteves A M, Simpson L. Uridine insertion/deletion RNA editing in trypanosome mitochondria a review. Gene 1999; 240: 247-60.
4. Morris JC, Drew ME, Klingbeil MM, Motyka SA, Saxowsky TT, Wang Z, et al. Replication of kinetoplast DNA: An update for the new millennium. Int J Parasitol 2001; 31: 453-8.
5. Kingbeil MM, Drew ME, Liu Y, Morris JC, Motyka SA, Saxowsky TT, et al. Unlocking the secrets of trypanosome kinetoplast DNA network replication. Protist 2001; 152: 255-62.
6. Shlomai J. The structure and replication of kinetoplast DNA. Curr Mol Med 2004; 4: 623-47.
7. Liu B, Liu Y, Motyka SA, Agbo EEC. Englund PT. Fellowship of the rings: the replication of kinetoplast DNA. Trends Parasitol 2005; 21: 363-69.
8. Liu Y, Englund PT. The rotational dynamics of kinetoplast DNA replication. Mol Microbiol 2007; 64: 676-90.
9. Hajduk S L, Klein VA, Englund PT. Replication of kinetoplast DNA maxicircles. Cell 1984; 36: 483-92.
10. Carpenter LR, Englund PT. Kinetoplast maxicircle DNA replication in Crithidia fasciculata and Trypanosama brucei. Mol Cell Biol 1995; 15: 6794-6803.
11. Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-40.
12. Cortes F, Pastor N, Mateos S, Dominguez I. Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutant Res 2003; 543: 59-66.
13. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665-97.
14. Maxwell A, Gellert M. Mechanistic aspects of DNA topoisomerases. Adv Protein Chem 1986; 38: 69-107.
15. Champoux JJ. DNA topoisomerases: Structure, function and mechanism. Annu Rev Biochem 2001; 70: 369-413.
16. Bergerat A, de Massy B, Gadelle D, Varoutas PC, Nicolas A, Forterre P. An atypical topoisomerase II from archaca with implications for meiotic recombination. Nature 1997; 386: 414-7.
17. Buhler C, Gadelle D, Forterre P, Wang JC, Bergerat A. Reconstitution of DNA topoisomerase VI of the thermophilic archeon Sulfolobus shibatae from subunits separately overexpressed in Escherichia coli. Nucleic Acids Res 1998; 26: 5157-62.
18. Drlica K, Franco RJ. Inhibitors of DNA topoisomerases. Biochem 1988; 27: 2253-59.
19. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-75.
20. Nenortas E, Bodley AL, Shapiro TA. DNA topoisomerases: A new twist for antiparasitic chemotherapy? Bioch Biophy Acta 1998; 1400: 349-54.
21. Das A, Dasgupta A, Sengupta T, Majumder HK. Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trens Parasitol 2004; 20: 381-87.
22. Lourenço EE, Cavalcanti DP, Picchi GFA, De Souza W, Krieger MA, Motta MCM, et al. Molecular characterization of type II topoisomerase in the endosymbiont-bearing trypanosomatid. Blastocrithidia culicis. FEMS Microbiol Lett 2006; 257: 163-70
23. Pasion SG, Hines JC, Aebersold R, Ray DS. Molecular cloning and expression of the gene encoding the kinetoplast-associated type II DNA topoisomerase of Crithidia fasciculata. Mol Biochem Parasitol 1992; 50: 57-68.
24. Broccoli S, Marquis JF, Papadopoulou B, Olivier M, Drolet M. Characterization of a Leishmania donovani gene enconding a protien that closely reseables a type IB topoisomerase. Nucleic Acids Res 1999; 27: 2745-52.
25. Das A, Dasgupta A, Sharma S, Ghosh M, Sengupta T, Bandopadhyay S, et al. Characterisation of the gene encoding type II DNA topoisomerase from Leishmania donovani: A key molecular target in antileishmanial therapy. Nucleic Acids Res 2001; 29: 1844-51.
26. Hanke T, Ramiro MJ, Trigueros S, Roca J, Larraga V. Cloning, functional analysis and post-transcriptional regulation of a type II DNA topoisomerase from Leishmania infantum: A new potential target for anti-parasite drugs. Nucleic Acids Res 2003; 31: 4917-28.
27. Strauss PR, Wang JC. The TOP2 gene of Trypanosoma brucei: A single-copy gene that shares extensive homology with other TOP2 genes encoding eukaryotic DNA topoisomerase II. Mol Biochem Parasitol 1990; 38: 141-50.
28. Bodley AL, Chakraborty AK, Xie S, Burri C, Shapiro TA. An unusual type IB topoisomerase from African trypanosomes. Proc Natl Acad Sci USA 2003; 100: 7539-44.
29. Douc-Rasy S, Kayser A, Riou J, Riou G. ATP-independent type II topoisomerase from trypanosomes. Proc Natl Acad Sci USA 1986; 83: 7152-56.
30. Fragoso SP, Goldenberg S. Cloning and characterization of the gene encoding Trypanosoma cruzi DNSA topoisomerase II. Mol Biochem Parasitol 1992; 55: 127-34.
31. Melendy T, Sheline C, Ray DS. Localization of a type II DNA topoisomerase to two sites of the periphery of the kinetoplast DNA of Crithidia fasciculata. Cell 1988; 55: 1083-88.
32. Fragoso SP, Mattei D, Hines JC, Ray D, Goldenberg S. Expression and cellular localization of Trypanosoma cruzi type II DNA topoisomerase. Mol Biochem Parasitol 1998; 94: 197-204.
33. Cavalcanti DP, Fragoso SP, Goldenberg S, De Souza W, Motta MCM. The effect of topoisomerase II inhibitors on the kinetoplast ultrastructure. Parasitol Res 2004; 94: 439-48.
34. Sugino A, Higgins N, Browns P, Peebles C, Cozzarelli N. Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci USA 1978; 75: 4838-42.
35. Sugino A, Peebles C, Kruezer K, Cozzarelli N. Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci USA 1977; 74: 4767-71
36. Gellert M, O'Dea MH, Itoh T, Tomizawa J. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci USA 1976; 73: 4474-78.
37. Hsieh T, Brutlag D. ATP-dependent DNA topoisomerase from D. melanogaster reversibly catenates duplex DNA rings. Cell 1980; 21: 115-25.
38. Kaufmann SH. Cell death induced by topoisomerase-targeted drugs: More questions than answers. Biocchem Acta 1998; 1400: 195-211.
39. Gellert M, Mizzuuchi K, O'Dea M H, Itoh T, Tomizawa J. Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 1977; 74: 4772-6.
40. Hsiang Y, Hertzberg S, Liu L. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-8.
41. Bodley AL. Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem Pharmacol 1995; 50: 937-42
42. Bodley AL, Shapiro TA. Molecular and cytotoxic effects of camptothecin, a topoisomerase 1 inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci USA 1995; 92: 3726-30.
43. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259: 9182-87.
44. Grabowski DR, Holmes KA, Aoyama M, Yee Y, Rybicki LA, Bukowski RM, et al. Altered drug interaction and regulation of topoisomerase Hβ: potential mechanisms, governing sensitivity of HL-60 cells to amsacrine and etoposide. Mol Pharmacol 1999; 56: 1340-45.
45. Riou GF, Gabillot M, Douc-Rassy S, Kayser A, Barrois M. A type I topoisomerase from Trypanosoma cruzi. Eur J Biochem 1983; 134: 479-84.
46. Chakraborty AK, Gupta A, Majumber HK. A type I DNA topoisomerase from the kinetoplast hemoflagellate Leishmania donovani. Indian J Biochem Biophys 1993; 30: 257-63.
47. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 1991; 51: 6039-44.
48. Sinkantaramas S, Asano T, Sudo H, Yamazaki M, Saito K. Camptothecin: therapeutic potential and biotechnology. Curr Pharm Biotechnol 2007; 8: 196-202.
49. Ray S, Majumder HK, Chakravarly AJ, Mukhopadhyay S, Gil RR, Cordell GA. Amaroggentin, a naturally occuring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovani. J Nat Prod 1996; 59:27-9.
50. Koster DA, Palle K, Bot ES, Bjornsti MA, Dekker NH. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 2007; 446: 213-17.
51. Yanaihara T, Onoda S, Yamamoto M, Ryuge, S, Hagiri S, Katagiri M, et al. Phase I and pharmacologic study of innotecan and amrubicin in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2007; 59: 419-27.
52. Yardley V, Snowdon D, Croft SL, Hazra B. In vitro activity of diospyrin and its derivatives against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei brucei. Phytother Res 1996; 10: 559-62.
53. Ray S, Hazra B, Mittra B, Das A, Majumder HK. Diospyrin, a bisnaphthoquinone: A novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Mol Pharmacol 1998; 54: 994-9.
54. Shapiro TA, Klein VA, Englund PT. Drug-promoted cleavage of kinetoplast DNA minicircles. J Biol Chem 1989; 264: 4173-8.
55. Ray DS, Hine JC, Anderson M. Kinetoplast-associated DNA topoisomerase in Crithidia fasciculata: Crosslinking of mitochondrial topoisomerase to both minicircles and maxicircles in cells treated with the topoisomerase inhibitor VP16. Nucleic Acids Res l992; 20: 3353-6.
56. Shapiro TA, Showalter AF. In vivo inhibition of trypanosome mitochondrial topoisomerase II: Effects on kinetoplast DNA maxicircles. Mol Cel Biol 1994: 14: 5891-7.
57. Li JH, Castora FJ. DNA topoisomerase II fro mammalian mitochondran is inhibited by the nntitunior drugs, m-AMSA and VM-26. Biocbem Biophy Res Commun 1991; 176: 690-7.
58. Figgitt D, Denny W, Chavalitshewinkoon P, Wilairat P, Ralph R. In vitro study or anticancer acridines as potential antitrypanosomal and antimalarial agents. Antimicrob Agents Chemother 1992; 36: 1044-7.
59. Lewis RJ, Tsai FT, Wigley, DB. Molecular mechanisms of drug inhibition of DNA gyrase. Bioessays 1996; 16: 661-71.
60. Maxwell A. DNA gyrase as a target. Biochem Soc Trans 1999; 27: 48-53
61. Gonzales-Perdomo M, Castro SL, Meirelles MNSL, Goldenberg S. Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob Agents Chemother 1990; 34: 1707-14.
62. Croft SL, Hogg J. Limited activity of bacterial DNA topoisomerase II inhibitors against Leishmania donovani and Trypanosoma cruzi amastigotes in vitro. Trans R Soc Trop Med Hyg 1988; 82: 856.
63. Nenortas E, Burri C, Shapiro TA. Antitrypanosomal acitivity of fluoroquinolnes. Antimicrob Agents Chemother 1999; 43: 2066-68.
64. Ray S, Sandhukhan PK, Mandal NB, Mahato SB, Majumder HK. Dual inhibition of DNA topoisomerases of Leishmania donovani by novel indolyl quinolines. Biochem Biophys Res Commun (BBRC) 1997; 230: 171-5
65. Poddevin B, Riou JF, Lavelle F, Pommier Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol 1993; 44:767-74.
66. Leteurte F, Fujimori A, Tanizawa A, Chabra A, Mazumder A, Kohlhagen G, et al. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J Biol Chem 1994; 269: 28702-7.
67. Pate PG, Wolfson, JS, McHugh GL, Pan SC, Swartz MN. Novobiocin antagonism of amastiaotes of Trypanosoma cruzi growing in cell-free medium. Antimicrob Agents Chemother 1986; 29: 426-31.
68. Pardee AB, Li YZ, Li CJ. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2002; 2: 227-42.
69. Menna-Barreto RFS, Corrêa JR, Pinto AV, Soares MJ. Catro SL. Mitochondrial disruption and DNA fragmentation in Trypanosoma cruzi induced by naphthoimidazoles synthesized from β-lapachone. Parasitol Res 2007; 101: 895-905.
70. Guttman HN, Eisenman RN. Acriflavine-induced loss of kinetoplast DNA in Crithidia fasciculata. Nature 1965: 207: 1280-1.
71. Simpson L. Effect of acriflavin on the kinetoplast of Leishmania tarentolae. J Cell Biol 1968: 37: 660-82.
72. Robertson M. The action of acriflavine upon Bodo caudatus. Parasitol 1929; 21: 375-416
73. Inoki S, Sakamoto H, Ono T, Kubo R. Studies on the Ak forms of Trypanosoma evansi. I. Effect of acriflavine on the appearance of the Ak forms. Biken's J 1961; 4: 67-73.
74. Trager W, Rudzinska MA. The riboflavin requirement and the effects of acriflavin on the fine structure of the kinetoplast of Leishmania tarentolae. J Protozool 1964; 11: 133-45.
75. Stuart KD. Evidence for the retention of kinetoplast DNA in an acriflavine-induced dyskinetoplastic strain of Trypanosoma brucei which replicates the altered central element of the kinetoplast. J Cell Biol 1971; 49: 189-95.
76. Hajduk SL. Dyskinetoplasty in two species of trypanosomatids. J Cell Sci 1979; 35: 185-202.
77. Schnaufer A, Domingo GJ, Stuat K. Natural and induced dyskine-toplastic
78. Hill GC, Anderson WA. Effects of acriflavine on the mitochondrion and kinetoplast of Crithidia fasciculata. Correlation oi the fine structure changes with decreased mitochondrial enzyme activity J Cell Biol 1969; 41: 547-61.
79. Bacchi CJ, Hill GC. Crithidia fasciculata: Acriflavine-induced changes in soluble enzymes. Exp Parasitol 1972; 31: 290-8.
80. Thirion J, Kupersztejn R. Etude des effets de lácriflavine et du bromure d'éthidium sur l'áppareil respiratoire du trypanosomide "Crithidia luciliae". Arch Int Physiol Biochim 1968; 76: 387-88.
81. Manaia AC, Roitman I. Effect of ethidium bromide on the oxidative metabolism and enzyme profiles of Crithidia fasciculata. J Protozool 1977; 24: 192-5.
82. Riou GF, Belnat P, Benard J. Complete loss of kinetoplast DNA sequences by ethidium bromide or by acriflavine in Trypanosoma equiperdum. J Biol Chem 1980; 255: 5141-4.
83. Hajduk SL. Influence of DNA complexing compounds on the kinetoplast of trypanosomatids. Prog Mol Subcell Biol 1978; 6: 156-200.
84. Dervan PB. Design of sequence-specific DNA-binding molecules. Science 1986; 232: 464-71.
85. Neidle S, Pearl LH, Skelly JV. DNA structure and perturbation by drug binding. Biochem J 1987; 243:1-13
86. Portugal P. Berenil acts as a poison of eukaryotic topoisomerase II. FEBS Lett 1994; 344: 136-8.
87. Woynarowski JM, Mc Hugh M, Sigmund RD, Beerman TA. Modulation of topoisomerase II catalytic activity by minor groove binding agents distamycin, Hoechst 33258, and 4′, 6-diamidine-2-phenylindole. Mol Pharmacol 1989; 35: 177-82.
88. Fairfield FR, Bauer WR, Simpson MV. Mitochondria contain a distinct DNA topoisomerase. J Biol Chem 1979; 254: 9352-4.
89. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-8
90. Shapiro TA, Englund PT. Selective cleavage of Kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proc Natl Acad Sci USA 1990; 87: 950-4.
91. D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990; 50: 6919-24.
92. Li CJ, Li Y, Pinto AV, Pardee AB. Potent inhibition of tumor survival in vivo by β-lapachone plus taxol: Combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA 1999; 96: 13369-74.
93. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ. Selective killing of cancer cells by β-lapachone: Direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA 2003; 100: 2674-8.
94. Woodward R, Gull K. Timing of nuclear and kinetoplast DNA replication and early morphological events in the cell cvcle of Trypanosoma brucei. J Cell Sci 1990; 95: 49-57.